By virtue of increased dosage and metabolism of the Hsa21 gene product, amyloid precursor protein (APP), people with DS will show neurohistopathological hallmarks of AD by as young as 8–12 years of age and many, but not all, will proceed to a clinical diagnosis of dementia about four to five decades later [63]. This evidence concerns the gene APP and Dravet syndrome.